Arcutis Biotherapeutics(ARQT) - 2024 Q2 - Quarterly Results

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update • Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 '23 and 43% vs. Q1 '24 • Continued gross-to-net (GTN) improvement with blended GTN across products now in the high 50 percent range, improving from the low 60 percent range last quarter • Sustained growth in prescriptions f ...